Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

2.05
+0.290016.48%
Post-market: 1.92-0.1300-6.34%19:58 EST
Volume:9.16M
Turnover:18.98M
Market Cap:169.22M
PE:-0.80
High:2.25
Open:1.85
Low:1.82
Close:1.76
Loading ...

Company Profile

Company Name:
Editas Medicine
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
265
Office Location:
11 Hurley Street,Cambridge,Massachusetts,United States
Zip Code:
02141
Fax:
- -
Introduction:
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Directors

Name
Position
James Mullen
Director and Chairman
Katrine Bosley
Director,President and Chief Executive Officer
Akshay K. Vaishnaw
Director
Andrew Hirsch
Director
Boris Nikolic
Director
Jessica Hopfield
Director

Shareholders

Name
Position
Katrine Bosley
Director,President and Chief Executive Officer
Andrew A. F. Hack
Chief Financial Officer
Charles Albright
Chief Scientific Officer
Gerald Cox
Chief Medical Officer